标题：多发性骨髓瘤患者的血清β2-MG、TNF-α、IL-6水平及其临床意义

      作者：王丽 1，赵艳莉 2，金瑄 3，赵莉平 4    1.陕西中医药大学附属医院检验科，陕西 咸阳 712000；2.陕西中医药大学附属医院肿瘤一科，陕西 咸阳 712000；3.陕西中医药大学附属医院儿科，陕西 咸阳 712000；4.陕西中医药大学医学技术学院，陕西 咸阳 712000

      卷次： 2020年31卷12期

      【摘要】 目的 观察多发性骨髓瘤(MM)患者的血清β2-微球蛋白(β2-MG)、肿瘤坏死因子-α (TNF-α)及白介素-6 (IL-6)水平，并探讨其临床意义。方法 选择陕西中医药大学附属医院2017年1月至2019年10月期间收治的92例MM患者纳入观察组，选择同期在我院体检的90例健康志愿者作为对照组。观察组于化疗前后，对照组于入组次日抽取空腹静脉血，测定并比较两组受检者的血清β2-MG、TNF-α、IL-6水平。结果 化疗前，观察组患者的血清β2-MG、TNF-α、IL-6水平分别为(9.28±3.52) mg/L、(168.52±41.73) pg/mL、(106.18±31.35) pg/mL，明显高于对照组的(1.64±0.48) mg/L、(79.84±23.97) pg/mL、(42.11±14.36) pg/mL，差异均有统计学意义(P<0.05)；血清β2-MG、TNF-α、IL-6水平随着MM患者Durie-Salmon分期加重逐渐增高，差异均有统计学意义(P<0.05)；化疗后，MM患者和血清β2-MG、TNF-α、IL-6水平分别为(6.15±2.36) mg/L、(109.34±34.27) pg/mL、(82.04±27.72) pg/mL，明显低于化疗前，差异均有统计学意义(P<0.05)。结论 多发性骨髓瘤患者血清 β2-MG、TNF-α、IL-6水平显著增高，且随病情程度加重出现升高趋势，可以用于MM的诊断及病情严重程度、预后的判断。
      【关键词】 多发性骨髓瘤；β2-微球蛋白；肿瘤坏死因子-α；白介素-6；预后；临床价值
      【中图分类号】 R733.3 【文献标识码】 A 【文章编号】 1003—6350（2020）12—1527—03

Clinical value of serum β2-microglobulin, TNF-α, and IL-6 levels in patients with multiple myeloma.
WANG Li 1,ZHAO Yan-li 2, JIN Xuan 3, ZHAO Li-ping 4. 1. Department of Clinical Laboratory, Affiliated Hospital of Shaanxi Universityof Traditional Chinese Medicine, Xianyang 712000, Shaanxi, CHINA; 2. First Department of Oncology, Affiliated Hospitalof Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, Shaanxi, CHINA; 3. Department of Pediatrics,Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, Shaanxi, CHINA; 4. School ofMedical Technology, Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, Shaanxi, CHINA
【Abstract】 Objective To investigate the clinical value of serum β2-microglobulin (β2-MG), tumor necrosis fac-tor-α (TNF-α), and interleukin-6 (IL-6) levels in patients with multiple myeloma. Methods Ninety-two patients withmultiple myeloma who were treated in Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine fromJanuary 2017 to October 2019 were selected as the study objects and included into the observation group, and 90 healthyvolunteers who had physical examination in our hospital at the same time were selected as the control group. The se-rum β2-MG, TNF-α, and IL-6 levels were measured before and after chemotherapy in the observation group and at thenext day in the control group. Results The levels of serum β 2-MG, TNF-α, and IL-6 in the observation group were(9.28±3.52) mg/L, (168.52±41.73) pg/mL, (106.18±31.35) pg/mL, significantly higher than (1.64±0.48) mg/L, (79.84±23.97) pg/mL, (42.11±14.36) pg/mL in the control group (P<0.05). The levels of serum β 2-MG, TNF-α, and IL-6 in-creased with the increase of Durie-salmon stage in patients with multiple myeloma, and the difference was statisticallysignificant (P<0.05). After chemotherapy, the levels of serum β2-MG, TNF-α, and IL-6 in patients with multiple myelo-ma were (6.15±2.36) mg/L, (109.34±34.27) pg/mL, (82.04±27.72) pg/mL, significantly lower than those before chemo-therapy (P<0.05). Conclusion The levels of serum β 2-MG, TNF-α, and IL-6 in patients with multiple myeloma aresignificantly higher, and they tend to increase with the severity of the disease. It can be used for the diagnosis, and thejudgment of the severity and prognosis of multiple myeloma.
      【Key words】 Multiple myeloma; β 2-microglobulin (β 2-MG); Tumor necrosis factor-α (TNF-α); Interleukin-6(IL-6); Clinical value